Cargando…

Early-onset pancreatic cancer: a review of molecular mechanisms, management, and survival

Objectives: Early-onset pancreatic cancer (EOPC) – defined as pancreatic cancer diagnosed before the age of 50 years – is associated with a poor prognosis as compared to later-onset pancreatic cancer (LOPC). Emerging evidence suggests that EOPC may exhibit a genetic signature and tumor biology that...

Descripción completa

Detalles Bibliográficos
Autores principales: Ulanja, Mark B., Moody, Alastair E., Beutler, Bryce D., Antwi-Amoabeng, Daniel, Rahman, Ganiyu A., Alese, Olatunji B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9200435/
https://www.ncbi.nlm.nih.gov/pubmed/35720978
http://dx.doi.org/10.18632/oncotarget.28242
_version_ 1784728060148318208
author Ulanja, Mark B.
Moody, Alastair E.
Beutler, Bryce D.
Antwi-Amoabeng, Daniel
Rahman, Ganiyu A.
Alese, Olatunji B.
author_facet Ulanja, Mark B.
Moody, Alastair E.
Beutler, Bryce D.
Antwi-Amoabeng, Daniel
Rahman, Ganiyu A.
Alese, Olatunji B.
author_sort Ulanja, Mark B.
collection PubMed
description Objectives: Early-onset pancreatic cancer (EOPC) – defined as pancreatic cancer diagnosed before the age of 50 years – is associated with a poor prognosis as compared to later-onset pancreatic cancer (LOPC). Emerging evidence suggests that EOPC may exhibit a genetic signature and tumor biology that is distinct from that of LOPC. We review genetic mutations that are more prevalent in EOPC relative to LOPC and discuss the potential impact of these mutations on treatment and survival. Materials and Methods: Using PubMed and Medline, the following terms were searched and relevant citations assessed: “early onset pancreatic cancer,” “late onset pancreatic cancer,” “pancreatic cancer,” “pancreatic cancer genes,” and “pancreatic cancer targeted therapy.” Results: Mutations in CDKN2, FOXC2, and SMAD4 are significantly more common in EOPC as compared to LOPC. In addition, limited data suggest that PI3KCA mutations are more frequently observed in EOPC as compared to LOPC. KRAS mutations are relatively rare in EOPC. Conclusions: Genetic mutations associated with EOPC are distinct from those of LOPC. The preponderance of the evidence suggest that poor outcomes in EOPC are related both to advanced stage of presentation and unique tumor biology. The molecular and genetic features of EOPC warrant further investigation in order to optimize management.
format Online
Article
Text
id pubmed-9200435
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-92004352022-06-17 Early-onset pancreatic cancer: a review of molecular mechanisms, management, and survival Ulanja, Mark B. Moody, Alastair E. Beutler, Bryce D. Antwi-Amoabeng, Daniel Rahman, Ganiyu A. Alese, Olatunji B. Oncotarget Review Objectives: Early-onset pancreatic cancer (EOPC) – defined as pancreatic cancer diagnosed before the age of 50 years – is associated with a poor prognosis as compared to later-onset pancreatic cancer (LOPC). Emerging evidence suggests that EOPC may exhibit a genetic signature and tumor biology that is distinct from that of LOPC. We review genetic mutations that are more prevalent in EOPC relative to LOPC and discuss the potential impact of these mutations on treatment and survival. Materials and Methods: Using PubMed and Medline, the following terms were searched and relevant citations assessed: “early onset pancreatic cancer,” “late onset pancreatic cancer,” “pancreatic cancer,” “pancreatic cancer genes,” and “pancreatic cancer targeted therapy.” Results: Mutations in CDKN2, FOXC2, and SMAD4 are significantly more common in EOPC as compared to LOPC. In addition, limited data suggest that PI3KCA mutations are more frequently observed in EOPC as compared to LOPC. KRAS mutations are relatively rare in EOPC. Conclusions: Genetic mutations associated with EOPC are distinct from those of LOPC. The preponderance of the evidence suggest that poor outcomes in EOPC are related both to advanced stage of presentation and unique tumor biology. The molecular and genetic features of EOPC warrant further investigation in order to optimize management. Impact Journals LLC 2022-06-15 /pmc/articles/PMC9200435/ /pubmed/35720978 http://dx.doi.org/10.18632/oncotarget.28242 Text en Copyright: © 2022 Ulanja et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Review
Ulanja, Mark B.
Moody, Alastair E.
Beutler, Bryce D.
Antwi-Amoabeng, Daniel
Rahman, Ganiyu A.
Alese, Olatunji B.
Early-onset pancreatic cancer: a review of molecular mechanisms, management, and survival
title Early-onset pancreatic cancer: a review of molecular mechanisms, management, and survival
title_full Early-onset pancreatic cancer: a review of molecular mechanisms, management, and survival
title_fullStr Early-onset pancreatic cancer: a review of molecular mechanisms, management, and survival
title_full_unstemmed Early-onset pancreatic cancer: a review of molecular mechanisms, management, and survival
title_short Early-onset pancreatic cancer: a review of molecular mechanisms, management, and survival
title_sort early-onset pancreatic cancer: a review of molecular mechanisms, management, and survival
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9200435/
https://www.ncbi.nlm.nih.gov/pubmed/35720978
http://dx.doi.org/10.18632/oncotarget.28242
work_keys_str_mv AT ulanjamarkb earlyonsetpancreaticcancerareviewofmolecularmechanismsmanagementandsurvival
AT moodyalastaire earlyonsetpancreaticcancerareviewofmolecularmechanismsmanagementandsurvival
AT beutlerbryced earlyonsetpancreaticcancerareviewofmolecularmechanismsmanagementandsurvival
AT antwiamoabengdaniel earlyonsetpancreaticcancerareviewofmolecularmechanismsmanagementandsurvival
AT rahmanganiyua earlyonsetpancreaticcancerareviewofmolecularmechanismsmanagementandsurvival
AT aleseolatunjib earlyonsetpancreaticcancerareviewofmolecularmechanismsmanagementandsurvival